甲磺酸仑伐替尼
Tier A — Act nowLenvatinib Mesilate · all drugs expiring in 2028 →
Targets：VEGFR1、KIT、VEGFR3、FGFR4、FGFR1、FGFR3、FGFR2、VEGFR2、PDGFR-α、RET
Brand：乐卫玛、Lenvima、Kisplyx、Lenvima/Kisplyx
Indications (approved)：肾细胞癌、子宫内膜癌、肝细胞癌、甲状腺瘤
Regional status
Synthetic routes & intermediates3 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| LENT-001 | 20925-27-3Available | 4-amino-2-chlorobenzonitrile |
| LENT-002 | 7251-09-4Available | 4-amino-2-methoxybenzonitrile |
| LENT-003 | 15568-86-2Available | 5-(ethoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione |
| LENT-004 | 417721-14-3Available | 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino)-2-methoxybenzonitrile |
| LENT-005 | 417721-15-4Available | 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carbonitrile |
| LENT-006 | 417721-34-7Available | 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid |
| LENT-007 | 417721-35-8Available | 4-chloro-7-methoxyquinoline-6-carbonyl chloride |
| LENT-008 | 417721-36-9Available | 4-chloro-7-methoxyquinoline-6-carboxamide |
| LENT-009 | 17609-80-2Available | 4-amino-3-chlorophenol |
| LENT-010 | 417722-93-1Available | 4-(4-amino-3-chlorophenoxy)-7-methoxyquinoline-6-carboxamide |
| LENT-011 | 1885-14-9Available | phenyl carbonochloridate |
| LENT-012 | 417722-95-3Available | phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate |
| LENT-013 | 86483-52-5Available | cyclopropanamine |
| Code | CAS No. | Intermediate |
|---|---|---|
| LENT-008 | 417721-36-9Available | 4-chloro-7-methoxyquinoline-6-carboxamide |
| LENT-009 | 17609-80-2Available | 4-amino-3-chlorophenol |
| LENT-013 | 86483-52-5Available | cyclopropanamine |
| LENT-016 | 201811-58-7Available | tert-butyl (2-chloro-4-hydroxyphenyl)carbamate |
| LENT-017 | 1808104-64-4Available | tert-butyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate |
| LENT-018 | 1808104-65-5Available | 4-(4-amino-3-chlorophenoxy)-7-methoxyquinoline-6-carboxamide hydrochloride |
| Code | CAS No. | Intermediate |
|---|---|---|
| LENT-008 | 417721-36-9Available | 4-chloro-7-methoxyquinoline-6-carboxamide |
| LENT-009 | 17609-80-2Available | 4-amino-3-chlorophenol |
| LENT-011 | 1885-14-9Available | phenyl carbonochloridate |
| LENT-013 | 86483-52-5Available | cyclopropanamine |
| LENT-014 | 796848-80-1Available | phenyl (2-chloro-4-hydroxyphenyl)carbamate |
| LENT-015 | 796848-79-8Available | 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea |
Frequently asked questions
What are the approved indications of Lenvatinib Mesilate?
Approved indications include: 肾细胞癌, 子宫内膜癌, 肝细胞癌, 甲状腺瘤.
When does the Lenvatinib Mesilate patent expire?
Based on public sources, the Lenvatinib Mesilate patent expires in 2028.
How many synthesis routes are recorded for Lenvatinib Mesilate?
3 synthesis routes are recorded; the shortest is 4 steps with 7.78 kg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Lenvatinib Mesilate intermediates?
18 intermediate CAS of Lenvatinib Mesilate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Lenvatinib Mesilate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24